Mechanism of small molecule inhibition of Plasmodium falciparum myosin A informs antimalarial drug design

Moussaoui, Dihia; Robblee, James P.; Robert-Paganin, Julien; Auguin, Daniel; Fisher, Fabio; Fagnant, Patricia M.; Macfarlane, Jill E.; Schaletzky, Julia; Wehri, Eddie; Mueller-Dieckmann, Christoph; Baum, Jake; Trybus, Kathleen M.; Houdusse, Anne

doi:10.1038/s41467-023-38976-7

Download PDF

Article
Open access
Published: 12 June 2023

Mechanism of small molecule inhibition of Plasmodium falciparum myosin A informs antimalarial drug design

Nature Communications volume 14, Article number: 3463 (2023) Cite this article

3845 Accesses
1 Citations
39 Altmetric
Metrics details

Subjects

Abstract

Malaria results in more than 500,000 deaths per year and the causative Plasmodium parasites continue to develop resistance to all known agents, including different antimalarial combinations. The class XIV myosin motor PfMyoA is part of a core macromolecular complex called the glideosome, essential for Plasmodium parasite mobility and therefore an attractive drug target. Here, we characterize the interaction of a small molecule (KNX-002) with PfMyoA. KNX-002 inhibits PfMyoA ATPase activity in vitro and blocks asexual blood stage growth of merozoites, one of three motile Plasmodium life-cycle stages. Combining biochemical assays and X-ray crystallography, we demonstrate that KNX-002 inhibits PfMyoA using a previously undescribed binding mode, sequestering it in a post-rigor state detached from actin. KNX-002 binding prevents efficient ATP hydrolysis and priming of the lever arm, thus inhibiting motor activity. This small-molecule inhibitor of PfMyoA paves the way for the development of alternative antimalarial treatments.

Plasmodium myosin A drives parasite invasion by an atypical force generating mechanism

Article Open access 23 July 2019

A 4-cyano-3-methylisoquinoline inhibitor of Plasmodium falciparum growth targets the sodium efflux pump PfATP4

Article Open access 16 July 2019

Reaction hijacking inhibition of Plasmodium falciparum asparagine tRNA synthetase

Article Open access 31 January 2024

Introduction

Malaria infection in humans, caused by unicellular parasites from the genus Plasmodium and transmitted via the bite of an infected Anopheles mosquito, is a major global health challenge^1,2. In 2020, malaria was responsible for 627,000 deaths, the majority being children under the age of 5 years³. Despite the remarkable progress of research aimed at advancing antimalarial therapeutics, the parasite continues to develop resistance to all existing treatments, including the gold-standard front line artemisinin-based combination therapies (ACTs)^4,5. The recent licensure of the malaria vaccine marks a significant milestone in efforts to control malaria, but the relatively modest efficacy of the RTS,S vaccine means that complementary approaches will be essential if the WHO’s goal of a 90% reduction in rates by 2030 is to be realized⁶.

Malaria parasites are motile throughout their complex human and mosquito life cycle. They move by a process called gliding motility⁷, which underpins their ability to reach, cross, and enter host tissues and cells. Gliding is powered by a macromolecular complex called the glideosome, the core of which is comprised of a class XIV myosin A (PfMyoA) interacting with short, oriented filaments of a divergent actin (PfAct1)^7,8. Importantly, PfMyoA has been demonstrated to be essential for parasite motility and for pathogenesis^9,10,11,12, thus making this myosin motor a desirable target for preventing lifecycle progression and as such malaria disease.

The development of small molecules able to specifically activate or inhibit myosin force production has been successful in several other myosin classes, including the activator omecamtiv mecarbil (OM) and the inhibitor mavacamten (CAMZYOS™), targeting β-cardiac myosin against heart failure and inherited cardiac diseases^13,14,15 and CK-571, a smooth muscle myosin 2 inhibitor (SmMyo2) against asthma¹⁶; reviewed by^17,18,19. From Structure Activity Relationship (SAR) on the Blebbistatin (Blebb) scaffold, MPH-220 was developed as a specific inhibitor of skeletal muscle myosin (SkMyo2) with promising therapeutical value against muscular spasticity²⁰. The fact that some of these compounds such as OM and mavacamten have completed phase 3 clinical trials^21,22 validates the development of myosins as realistic and druggable targets. Mavacamten (CAMZYOS™) has recently been approved by the FDA for the treatment of obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms.

Here, we characterize the interaction of PfMyoA with KNX-002, a small molecule inhibitor of PfMyoA ATPase activity and of P. falciparum merozoite asexual blood stage growth. KNX-002 was initially identified as an inhibitor from high-throughput actin-activated screens performed by Cytokinetics, Inc. The X-ray structure of PfMyoA complexed to KNX-002 identifies the binding pocket, and combined with transient kinetics and binding studies reveal how the compound sequesters PfMyoA in a state of low affinity for actin. KNX-002 is thus a promising candidate to develop an antimalarial treatment based on inhibiting the myosin motor that powers motile stages of the parasite, which are essential for infection.

Results

KNX-002 is a promising small molecule antimalarial inhibitor

KNX-002 was initially identified as an inhibitor of PfMyoA from high throughput actin-activated ATPase screens performed by Cytokinetics, Inc. using 50,000 compounds from their library. The same compounds were screened against TgMyoA in parallel, and upon completion of the screen KNX-002 was identified as a robust inhibitor of both class XIV myosins²³ (see Methods for screen details). KNX-002 inhibits both the actin activated (IC₅₀ = 7.2 µM) and the basal (IC₅₀ = 3.6 µM) ATPase activity of PfMyoA, while showing little effect on cardiac or skeletal myosin II (Fig. 1a, b). Measurement of the affinity of KNX-002 for nucleotide-free PfMyoA (8.6 µM) and PfMyoA.ADP (11.1 µM) yielded values (Supplementary Fig. 1a, b) that were of the same order of magnitude as the IC₅₀ obtained from the steady-state ATPase activities. KNX-002 also inhibited the ability of PfMyoA to move actin in an in vitro motility assay. In the absence of KNX-002 robust motility of actin filaments was observed at speeds of 3.33 ± 0.50 µm/s (Supplementary Movie 1), while there was no directed actin filament motion in the presence of 200 µM KNX-002 (Supplementary Movie 2). In addition, very few actin filaments were bound to surface-immobilized myosin in the presence of KNX-002 (6.5 ± 1.9 filaments/field versus 110.3 ± 1.9 filaments/field in its absence, n = 6 fields). In vitro TIRF polymerization assays further showed that KNX-002 did not affect PfAct1 filament assembly, which polymerized to similar lengths and at the same rate in the absence (16.6 ± 2.3 subunits/s, n = 36) or presence (17.2 ± 2.5 subunits/s; p = 0.28) of KNX-002.

Because PfMyoA is essential for blood cell invasion^9,10, we tested the effect of KNX-002 on P. falciparum asexual, blood-stage growth, an assay dependent on the ability of merozoites to invade erythrocytes²⁴. KNX-002 inhibited asexual blood stage growth of merozoites (IC₅₀ = 18.2 µM), confirming a drug effect on parasite cells ex vivo (Fig. 1c). Taken together, these results demonstrate that KNX-002 is an inhibitor of PfMyoA activity in vitro, as well as impeding asexual parasite blood stage growth that is a measure of the ability of parasites to invade, replicate, exit and reinvade erythrocytes, resulting in the symptomatic stage of malaria. The observation that KNX-002 inhibits actin-activated ATPase activity and parasite blood stage growth indicates that the compound inhibits myosin when physiological concentrations of nucleotide are present.

KNX-002 targets the post-rigor state

To dissect the inhibition mechanism of KNX-002 on the force production cycle, we crystallized full-length PfMyoA complexed with KNX-002. We successfully solved the structure of full-length PfMyoA complexed to both the ATP analog Mg.ATP-gamma-S (Mg.ATPγS) and KNX-002 (PfMyoA/ATPγS/KNX-002) at a resolution of 2.2 Å. The structure of full-length PfMyoA complexed to Mg.ATPγS without the compound (PfMyoA/ATPγS/Apo) was also solved at a resolution of 2.03 Å (Supplementary Table 1).

These experiments provide a direct comparison of the apo and the KNX-002-bound structures when a hydrolysable ATP analog is bound. The two datasets are both at high resolution and the resulting electron density maps allow us to determine that the PfMyoA structure adopts a post-rigor (PR) state, an ATP-bound myosin structural state with low affinity for the actin track that is populated upon detachment of the motor from actin prior to the priming of its lever arm (Supplementary Fig. 2). These high-resolution datasets also permitted us to position the nucleotides and KNX-002 without ambiguity, as well as the water molecules, in particular those in the active site (Fig. 2a, b). The two structures are highly superimposable (rmsd 0.2 Å on 914 Cα-atoms, Fig. 2c), indicating that KNX-002 does not induce major structural changes in the myosin structure. Some limited adjustments occur for the residues around the pocket upon KNX-002 binding (max difference in Cα positions being <2.5 Å, Supplementary Fig. 3a). The compound is close to the active site and interacts with Switch-2, an important connector of the motor that changes its conformation during the recovery stroke to favor ATP hydrolysis (Supplementary Fig. 2a, b).

**Fig. 2: KNX-002 targets the post-rigor (PR) state.**

The major difference between the apo and KNX-002-bound structures is the state of the nucleotide. While unhydrolyzed Mg.ATPyS occupies the active site of PfMyoA/ATPγS/KNX-002, the substrate was hydrolyzed in PfMyoA/ATPγS/Apo leaving only Mg.ADP in the active site (Fig. 2a, b). Because cleavage was only observed in the absence of compound, this result implies that KNX-002 directly inhibits the hydrolysis process.

To test this hypothesis, we performed manual quench experiments. In the presence of KNX-002, the phosphate burst is reduced 2.2-fold (Fig. 2d), which demonstrates the ability of KNX-002 to directly reduce ATP hydrolysis. In the motor cycle, ATP hydrolysis occurs after the recovery stroke. This ATP-bound transition is essential for lever arm priming and leads to the pre-powerstroke state (PPS) in which nucleotide-binding loops, notably Switch-2, are positioned to favor ATP hydrolysis (Supplementary Fig. 2). Our results suggest that KNX-002 inhibits hydrolysis by stabilizing the post-rigor state, thus blocking the recovery stroke. This agrees with our observation that attempts at crystallizing the motor in the presence of KNX-002 when the motor adopts the pre-powerstroke state (see Methods) lead to crystals lacking compound. In fact, the conformation of the KNX-002 binding pocket is drastically different in the PPS state and thus becomes incompetent for KNX-002 binding (Supplementary Fig. 3b).

The KNX-002 binding pocket

In the PfMyoA/ATPγS/KNX-002 structure, KNX-002 is buried in a tight cryptic cleft located between the so-called Upper 50 kDa (U50) and Lower 50 kDa (L50) subdomains of the motor domain, both of which have elements that bind the actin filament. KNX-002 is bound in the “inner cleft” (Figs. 2a and 3a), close to the so-called back-door of myosin^25,26 that is located near the yP_i of the nucleotide (Fig. 3a). Supplementary Fig. 2a illustrates the distinct conformations of the backdoor in the post-rigor and the pre-powerstroke states of the motor cycle. Specific connectors essential in allosteric transduction^26,27 are directly involved in the binding of KNX-002: Switch-1, Switch-2 and Transducer (Fig. 3a). This structure reveals a small-molecule co-crystallized in the PR state while binding near Switch-2. Most myosin inhibitors described to date target the PPS state of the myosin cycle^14,20,28.

**Fig. 3: The inner pocket in which KNX-002 binds greatly differs from that of Blebbistatin (Blebb).**

Binding of the KNX-002 molecule, comprised of four moieties (Fig. 1b), appears to be stabilized mainly by the hydrophobic effect: the methoxyphenyl (D) and the methylcyclopropamine (C) are sandwiched between apolar groups of residues from the Switch-1, β7 strand of the Transducer and the ɸLL-linker, a highly conserved linker located after the _Transducerβ7 and on the U50 side (Supplementary Fig. 3c), as well as apolar residues from the ^L50HP- and ^L50HW-helices (Fig. 3a, b, Supplementary Table 2). A polar interaction is established between the carbonyl of Leu272 and the methylcyclopropamine (C). The pyrazole (B) and thiophene moieties (A) are stacked between residues from the β5 and β6 strands of the Transducer, the ^L50HW-helix with contribution of Switch-2. Amongst these interactions, the most remarkable are established by the pyrazole (B), as it is involved in (i) a polar interaction with a water molecule coordinating the γ-P_i of the nucleotide and (ii) π-stacking electrostatic interactions with _Switch-2Phe471 (Fig. 3a, b, Supplementary Table 2). The tight fit of KNX-002 in this pocket is remarkable because all four cyclic entities make at least one contact within a radius of ~3.4 Å with atoms of the pocket.

In addition to the small main-chain shifts to adopt the size of the pocket around KNX-002 (Supplementary Fig. 3a), side chains of key-binding residues rotate to fit KNX-002 binding (Fig. 3c). This is specifically true for _Switch-2Phe471, _ɸLL-linkerLeu271 and _HW-helixPhe645 (Fig. 3c).

The KNX-002 binding mode differs from that described for Blebbistatin

It is important to describe how the Myo2 inhibitor Blebbistatin (Blebb) and KNX-002 binding modes differ because they involve similar PfMyoA structural elements. Indeed, the Blebb binding pocket also involves the Switches-1 and −2, the Transducer and ɸLL-linker, as well as the HP- and HW-helices (Fig. 3d, e). However, while the binding of KNX-002 and Blebb partially involve the same residues, the pockets conformations are in fact very different (Supplementary Movie 3) and thus KNX-002 cannot fit in the Blebb pocket and vice-versa (Fig. 3f). The two compounds indeed target distinct structural ATP-states of the motor: KNX-002 binds the PR state while Blebb targets the PPS state^20,28 (Supplementary Table 3). Moreover, Blebb and KNX-002 have different scaffolds and although binding of both mainly involve apolar interactions, the nature of the interactions and the residues involved differ (Fig. 3b, e, g). In addition, the nature of the few polar interactions is drastically different. For example, the hydroxyl moiety of Blebb is involved in essential electrostatic interactions with the amide of _Switch-1Gly240 and π-stacking interactions are established between Blebb and the _ɸLL-linkerY261 (Dd, 1YV3, Fig. 3e, g), while mostly apolar interactions are made with the PfMyoA equivalent _Switch-1Gly249and _ɸLL-linkerPhe270 residues and KNX-002. One polar contact occurs similarly in the two pockets with an equivalent carbonyl (_ɸLL-linkerL271 in PfMyoA and _ɸLL-linkerL262 in DdMyo2). The Switch-2 conformation as found in the pre-powerstroke state excludes the possibility of a direct bond between Blebb and the nucleotide or the Mg²⁺ ion. In contrast, specific interactions occur for KNX-002 with an ATP molecule bound to the active site when the Switch-2 adopts the conformation found in the post-rigor state. Taken together, these results clearly demonstrate that KNX-002 binds with a previously undescribed binding mode with unique features. An interesting characteristic of the KNX-002 pocket is that it involves a water molecule that directly binds the γ-P_i of the ATP molecule bound in the active site.

Sequence polymorphism between Myo2s and PfMyoA explain the specificity of the two inhibitors for their corresponding binding sites and result in different specific requirement for their binding mode (Supplementary Fig. 4a, b). In particular, KNX-002 specificity for PfMyoA results from major sequence changes compared to Myo2s: _Switch-2Phe471 in PfMyoA, involved in essential π-stacking interactions with KNX-002, is replaced by a serine or alanine in Myo2s (_Switch-2Ala463 in β-cardiac myosin); _ɸLL-linkerPhe270 in PfMyoA is replaced by a Tyrosine (_ɸLL-linkerTyr266 in β-cardiac myosin); _HP-helixPhe485 in PfMyoA is replaced by a cysteine in β-cardiac myosin (_HP-helixCys477) and _HP-helixLeu481 in PfMyoA is replaced by a Phenylalanine in β-cardiac myosin (_HP-helixPhe473) (Supplementary Fig. 4a, b). The Phe/Leu polymorphism in the HP-helix was reported to be responsible for the high specificity amongst Myo2s for a Blebb derivative of high therapeutical potential (MPH-220)²⁰. In addition, the HW-helix residues involved in binding are poorly conserved: _HW-helixPhe645 in PfMyoA is replaced by a Histidine in β-cardiac myosin (_HW-helixHis651). Such sequence differences allow each inhibitor to interact specifically in its tight pocket.

We validated this site and the role of some residues in KNX-002 binding and specificity with a triple mutant of PfMyoA. Three residues of the PfMyoA sequence were replaced by that of β-cardiac muscle myosin (Phe270Tyr/Phe471Ala/Phe645His) at key-positions for KNX-002 binding (Fig. 3g; Supplementary Fig. 4a, b). As in cardiac myosin (Fig. 1a), this triple mutant became less sensitive to KNX-002 compared with WT, with basal ATPase IC₅₀ increasing from 3.6 to 52 µM, and actin-activated ATPase IC₅₀ increasing from 7.2 to >100 µM (Supplementary Fig. 4c). The triple mutant showed intact heavy and light chains on an SDS-gel, and its functionality was assessed by an in vitro motility assay where it moved actin filaments with a Gaussian distribution of speeds that was the same in the presence or absence of KNX-002 (Supplementary Fig. 5). This result is consistent with the binding pocket of KNX-002 identified crystallographically, and suggests that some or all of these three key-aromatic positions are essential in the efficient binding and specificity of KNX-002 for PfMyoA. Interestingly, the specificity of KNX-002 for Class XIV myosins is also suggested by a sequence alignment with human unconventional myosins as differences are found for several residues involved in KNX-002 binding, including those that we have been mutated in the triple mutant (Supplementary Fig. 4b).

Impact of KNX-002 on the nucleotide binding site

Compared to Blebb, KNX-002 is positioned closer to the active site and the water that binds to its pyrazole group also participates in γP_i coordination and interacts with a water molecule involved in Mg²⁺ coordination (Fig. 4a, b). This suggests that KNX-002 may influence nucleotide binding rates and affinity, in addition to its hydrolysis. Transient kinetics were thus used to measure the association and dissociation rate constants of mant-ATP and mant-ADP for PfMyoA, nucleotides whose fluorescence is enhanced when bound to PfMyoA. KNX-002 caused a 4.8 and 3.3-fold decrease in the association rate constant for ATP and ADP, respectively, and small increases in the dissociation rate constants (Fig. 4c). The estimated Kd for ATP and ADP in the presence of KNX-002 was 0.7 μM and 3.5 μM, respectively, implying that under physiological nucleotide concentrations, motor with KNX-002 bound would also have nucleotide bound.

**Fig. 4: Effects of KNX-002 on the active site.**

The nucleotide binding experiments (Fig. 4c) and KNX-002 binding experiments (Supplementary Fig. 1) indicate that KNX-002 can bind nucleotide-free (NF) myosin in vitro and thus we determined NF PfMyoA structures bound to KNX-002 to investigate why nucleotides bind more slowly (Supplementary Fig. 6, Supplementary Table 1). Interestingly, the KNX-002 binding site is the same in the NF and the MgATPγS structures, suggesting that the compound traps myosin in similar post-rigor states regardless of nucleotide. Small local differences in the active site were found for residues involved in nucleotide binding (Supplementary Fig. 6). Comparison with MgATPγS-bound structures indicates that mobility in the active site would be required to facilitate nucleotide binding. Thus, the presence of KNX-002 in the inner cleft likely slows these rearrangements resulting in slower nucleotide binding. Our structures suggest that occupation of the nucleotide binding site and of the ligand binding site are not mutually exclusive, although KNX-002 likely slows motor domain dynamics, particularly in the active site.

Taken together, these results suggest that PfMyoA adopts a stable PR state when both ATP and KNX-002 are bound, in which the inner cleft cannot close, thus preventing the recovery stroke. The water near the pyrazole, observed in our PfMyoA-MgATPγS structure bound to KNX-002, is not in position to favor attack of the γ-P_i of ATP. The fact that both ATPγS and KNX-002 are compatible in the same structure and their mutual presence does not lead to hydrolysis of ATPγS indicates that KNX-002 prevents hydrolysis, most likely by perturbing the ability to favorably position the water molecule required for hydrolysis. The observation that KNX-002 separates the active site from _Switch-2Glu474 and slows Switch-2 rearrangements excludes a ATP hydrolysis mechanism that normally occurs in myosins, which requires the repositioning of Switch-2 during the recovery stroke so that the _switch-2glutamate can promote ATP hydrolysis by coordinating the attacking water molecule^29,30. Our structures thus provide a mechanistic explanation for how KNX-002 disfavors ATP hydrolysis.

PfMyoA.ADP has low affinity for F-actin in the presence of KNX-002

To investigate whether KNX-002 affects the stability of PfMyoA actin-bound states, we performed actin pull-down experiments using surface-bound PfMyoA (see Methods, Fig. 5a, Supplementary Figs. 8 and 9) in the presence of either ATP, ADP, or no nucleotide with or without KNX-002.

**Fig. 5: PfMyoA.ADP binds actin weakly in the presence of KNX-002.**

As expected, myosin binds few filaments in the presence of ATP, and KNX-002 does not change this property (Fig. 5a). In the absence of nucleotide (Nucleotide Free, NF), a similar large number of actin filaments are recruited in the absence (Apo) or presence of KNX-002. The absence of nucleotide allows myosin to bind actin with high affinity in the Rigor state, a state with the actin-binding cleft closed³¹ (Supplementary Fig. 2). Note that in this Rigor state, the ɸLL-linker directly interacts with the HP- and HW-helices and thus the KNX-002 binding site we identified does not exist. The observation that KNX-002 does not change the amount of actin bound to PfMyoA in NF conditions is consistent with the fact that PfMyoA stays bound in the Rigor state with the inner pocket closed, which would prevent KNX-002 binding (Fig. 5b). KNX-002 also does not affect the rate of ATP induced actomyosin dissociation, further suggesting that the compound is not compatible with the Rigor state (Supplementary Fig. 10) and instead binds a myosin state detached from F-actin. In ADP, fewer actin filaments are recruited compared to the NF condition. More importantly, the presence of both ADP and KNX-002 leads to a level of actin binding comparable to the weak binding observed with ATP (Fig. 5a). This result suggests that PfMyoA.ADP binds KNX-002 and prevents it from binding strongly to the F-actin track. Taken together, these results suggest that KNX-002 favors trapping the motor in a state of poor affinity for the actin track when nucleotide is bound.

Since actomyosin.ADP complexes are in equilibrium with detached M.ADP motors, it is likely that KNX-002 can bind these detached M.ADP motors as they explore conformational states that are close to the post-rigor state. KNX-002 binding would thus stabilize this state and prevent re-attachment to the actin filament in a Strong-ADP bound state. The structures currently available for distinct myosins in the Strong-ADP bound state²⁶ have indeed shown that the inner cleft is closed in these structures. Thus, KNX-002 binding in the inner cleft would prevent strong binding to the track (Fig. 5b).

Discussion

KNX-002 inhibits PfMyoA, a myosin shown from knockout experiments to be essential for Plasmodium falciparum invasion and motility, and thus represents a previously untapped target that could be used to prevent Plasmodium falciparum pathogenesis^9,10. The observation that KNX-002 ablates Plasmodium falciparum blood stage growth highlights the potential of targeting PfMyoA to develop future antimalarial drugs.

Previous studies of myosin inhibitors have shown that these compounds target binding pockets that are not always present in the apo form¹⁶ and that the accessibility of these cryptic pockets may vary depending on the myosin classes and the structural states targeted¹⁶. These reasons are why the binding mode of most myosin modulators cannot be predicted. Here we determine the cryptic pocket in which KNX-002 binds in PfMyoA via structural and biochemical data and validate it with directed mutagenesis. While KNX-002 and Blebb binding involves the same structural elements found in this inner pocket: i.e. Switch-1 and Switch-2, HP-helix, HW-helix and the ɸLL-linker, the conformation of these drug binding sites strongly differs (Supplementary Movie 3). This is due to the fact that the two compounds target different structural states, and because of sequence polymorphism between class 2 myosins and PfMyoA. Unlike Myo2 inhibitors such as Blebb and its derivatives that recognize this inner pocket in the conformation it adopts in the pre-power stroke state, KNX-002 binds when myosin adopts the post-rigor conformation, which structurally differs greatly from the pre-powerstroke state (Supplementary Movie 3). KNX-002 thus inhibits PfMyoA using a previously undescribed binding mode requiring residues of the inner pocket in the post-rigor state. Based on sequence alignments (Supplementary Table 4), this binding pocket appears to be conserved in MyoA from other apicomplexan parasites such as Toxoplasma (toxoplasmosis), Eimeria (coccidiosis), and Babesia (babesiosis) and thus derivatives of KNX-002 could ultimately be applicable to treatment of a number of parasitic diseases. Consistent with this idea, KNX-002 was recently reported to inhibit the motility and growth of the Toxoplasma gondii parasite in culture²³.

Interestingly, transient kinetics and structural data both demonstrate that the mechanism of action of KNX-002 and Blebb greatly differ (Supplementary Table 3). While Blebb inhibition comes from the occupation of the inner cleft that efficiently blocks the initiation of the powerstroke, it does not interfere with the recovery stroke or ATP hydrolysis^20,28,32. In contrast, KNX-002 steric occupation of the inner cleft in the post-rigor state pocket decreases ATP hydrolysis. KNX-002 indeed stabilizes a state of low affinity for actin in which binding to the inner cleft prevents the PfMyoA recovery stroke and prevents lever arm priming (Fig. 6). Our structure suggests that the molecular basis for reduced ATP hydrolysis includes slowing the recovery stroke and the inability of the motor to adopt the pre-powerstroke state, which is the most favorable to promote ATP hydrolysis by positioning a water molecule for in line attack of the γ-phosphate. Blebb and KNX-002 therefore belong to different categories of inhibitors with different mechanisms of action. KNX-002 represents a class of myosin inhibitors whose mode of action results from sequestering a post-rigor state. Trapping PfMyoA in a post-rigor state is sufficient to inhibit the activity since ATP hydrolysis does not occur in this state³³. This result opens the door for the potential discovery of distinct inhibitors for different myosin targets as we report here an efficient way of preventing myosin from participating in force production.

**Fig. 6: Mechanism of the inhibition by compound KNX-002.**

The ability of KNX-002 to inhibit asexual blood stage growth in vitro demonstrates its antimalarial activity, and validates that PfMyoA and other essential myosins are potential antiparasitic pharmacological targets^9,10,24,31. Moreover, KNX-002 was shown to not be toxic to human HepG2 liver cells at 80 µM²³. While the IC₅₀ for KNX-002 is in the micromolar range, these current data set a foundation for substantial further development with the structure of the PfMyoA bound to KNX-002 able to direct SAR that promote higher potency while conserving specificity. Thus, the structural data we provide paves the way to optimize this molecule for therapeutical potential. The biggest advantage of a strategy targeting PfMyoA with a KNX-002 derivative is that by inhibiting actin binding, it should efficiently slow motility and invasion phases of the parasite. A more potent derivative based on the KNX-002 scaffold (KNX-115) was recently characterized in vitro and in the Plasmodium parasite by James Spudich (CEO of Kainomyx) and colleagues³⁴. KNX-115 shows great promise as a therapeutic agent because it is parasiticidal at multiple stages of the Plasmodium lifecycle, acts on resistant Plasmodium strains and displays no liver cell toxicity³⁴. Structural studies of more potent KNX-002 derivatives will provide the blueprint for efficient PfMyoA inhibition and future development will aim to bring alternative prophylactic and/or symptomatic treatments. In addition, it will be essential to study how such potent inhibitors could bring a significant advantage either in conjunction with other antimalarials^35,36 or in conjunction with vaccination strategies that are unfortunately poorly efficient at present⁶.

Methods

Key resources

Key resources used in this study are tabulated in Supplementary Table 5.

KNX-002

KNX-002 (formerly CK2140597) was originally identified from high throughput screening of a library of 50,000 compounds at 40 µM final concentration (2% DMSO, v/v), performed by JS and EW at Cytokinetics, to identify inhibitors of the actin-activated ATPase of T. gondii MyoA (protein provided by Gary Ward, University of Vermont), and PfMyoA (protein provided by KMT). A coupled enzymatic ATPase assay⁹ was used for screening. Actin was polymerized using 1 mM ATP, 2 mM MgCl₂, 20 mM KCl and left on ice for 30 min. Solution A was made with PM12 (12 mM Pipes-KOH, pH 7.0, 2 mM MgCl₂), 1 mM DTT, 0.1 mg/ml BSA, 0.4 mM pyruvate kinase/lactate dehydrogenase, 1 mg/ml Myosin XIV, 0.009% Antifoam (Sigma-Aldrich). Solution B was made with PM12, 1 mM DTT, 0.1 mg/ml BSA, 1 mM ATP, 1 mM NADH, 1.5 mM phosphoenolpyruvate, 0.6 mg/ml actin previously polymerized and 0.009% Antifoam. 12.5 µl each of Solution A and B were added to a plate with a Packard MiniTrak liquid handler and then mixed at 2400 rpm for 45 s with a BioShake 3000 ELM orbital plate mixer (Qinstruments). The decrease in optical density at 340 nm as a function of time was measured on an Envision 2104 spectrophotometer (Perkin Elmer) with a 600 s data monitoring window sampled every 60 s. Hit progression included confirmation of activity in an independent experiment, inactivity against an unrelated ATPase (hexokinase), and dose-responsive inhibition. Hexokinase reactions were performed using glucose (1 mM) and sufficient hexokinase to generate ADP from ATP at a rate similar to the target myosins. Hit progression included confirmation of activity in an independent experiment, inactivity against an unrelated ATPase, and dose-responsive inhibition. Of note, KNX-002 was initially a weak hit in both campaigns due to a technical issue, but pursued for TgMyoA and later confirmed to be robustly active in both TgMyoA and PfMyoA assays, both with the initial library batch as well as with resupplied compound (>97% pure by LC/MS, Asinex). Kainomyx (www.kainomyx.com) licensed 6 compounds from Cytokinetics for drug discovery for malaria and other parasitic diseases, and James Spudich, CEO of Kainomyx, released CK2140597 (now KNX-002) without restrictions for academic studies in both the laboratories of Gary Ward, University of Vermont (for Toxoplasma), and KMT, University of Vermont (for Plasmodium). The KNX-002 used in this manuscript was custom-synthesized by Asinex (Winston-Salem, NC), and showed a high level of purity (97% pure), based on peak areas from a UV HPLC chromatogram at 275 nm using a Diode Array Detector.

Protein expression and purification

The full length PfMyoA heavy chain WT and triple mutant (Phe270Tyr/Phe471Ala/Phe645His) were co-expressed with a UCS (UNC-45/CRO1/She4p) family myosin chaperone from Plasmodium spp. and two light chains PfELC and PfMTIP³⁷. The full length PfMyoA heavy chain WT construct consists of the full Plasmodium myosin A heavy chain (PlasmoDB ID PF3D7_1342600/GenBank^TM accession number XM_001350111.1) with a 13-amino acid spacing linker (NVSPATVQPAFGS) followed by an 88-amino acid segment of the E. coli biotin carboxyl carrier protein^38,39 and a C-terminal FLAG tag. The PfMyoA heavy chain triple mutant (Phe270Tyr/Phe471Ala/Phe645His) was created by site-directed mutagenesis using this WT heavy chain gene as a template. The baculovirus transfer vector pAcSG2 (554769, BD Biosciences) was used to incorporate the PCR product to make recombinant baculovirus. The Plasmodium UCS family myosin chaperone is a chimeric clone that combines the coding sequence of P. falciparum (PF3D7_1420200/GenBank^TM accession number XM_001348333.1) with regions from P. knowlesi (PKNH_1337800/GenBank^TM accession number XM_002260772) in places where P. falciparum did not show consensus with other Plasmodium species. A Myc tag was added to the C-terminus and the resulting chimeric UCS chaperone PCR product was cloned into the baculovirus transfer vector pAcSG2 (554769, BD Biosciences) for recombinant virus production. The PfELC gene (PF3D7_1017500/GenBank^TM accession number XM_001347419.1) was PCR-amplified from gBlocks® gene fragments (Twist Bioscience) and inserted into the pFastBac vector (10359016, Thermo Fisher Scientific) for recombinant virus production. The PfMTIP gene (PF3D7_1246400/GenBank^TM accession number XM_001350813.1) was obtained from gBlocks® gene fragments (Twist Bioscience) and an N-terminal His₆ tag sequence added when cloning into the pAcSG2 vector (554769, BD Biosciences). For ΔN-MTIP, the N-terminal 60 amino acids were removed by site-directed mutagenesis, while retaining the N-terminal His₆ tag.

Sf9 cells (71104, Novagen) were infected with recombinant baculovirus and grown for 72 h in a medium containing 0.2 mg/ml biotin, harvested and lysed by sonication in 10 mM imidazole pH 7.4, 0.2 M NaCl, 1 mM EGTA, 5 mM MgCl₂, 7% (w/v) sucrose, 2 mM DTT, 0.5 mM 4-(2-aminoethyl) benzene-sulfonyl fluoride, 5 μg/ml leupeptin, 2 mM MgATP. An additional 2 mM MgATP was added prior to a clarifying spin at 200,000 × g for 40 min. The supernatant was then applied to an anti-FLAG-M2 affinity gel chromatography column (A2220, Sigma-Aldrich). The column was washed with 10 mM imidazole pH 7.4, 0.2 M NaCl, and 1 mM EGTA and the myosin eluted from the column using the same buffer plus 0.1 mg/ml FLAG peptide (A6002, APExBIO). The fractions containing myosin were pooled and concentrated using an Amicon centrifugal filter device (901024, Millipore), and dialyzed overnight against 10 mM imidazole, pH 7.4, 0.2 M NaCl, 1 mM EGTA, 55% (v/v) glycerol, 1 mM DTT, and 1 μg/ml leupeptin and stored at −20 °C.

Skeletal muscle actin was purified from chicken skeletal muscle tissue (frozen chicken breasts, Trader Joe’s) by processing the muscle tissue into an acetone powder followed by purification of actin from the acetone powder⁴⁰. Chicken breast tissue was ground with a meat grinder and suspended in 150 mM KPO₄ pH 6.7, 300 mM KCl, 2 mM EDTA, 1 mM DTT and 3 mM NaN₃. This slurry was added to a cheesecloth covered beaker and rinsed with 10 mM sodium bicarbonate and 0.1 mM CaCl₂. The tissue was washed with water and then with acetone and air dried overnight. The acetone powder was resuspended with G-buffer (5 mM Tris, pH 8.2 at 4 °C, 0.2 mM CaCl₂, 0.2 mM Na₂ATP, 0.5 mM DTT, 1 μg/ml leupeptin) and G-actin was extracted for 1 h at 4 °C, followed by centrifugation at 35,000 × g for 20 min. G-actin was polymerized to F-actin by addition of 2 mM MgCl₂ and 80 mM KCl (overnight, 4 °C). To remove tropomyosin, the KCl was increased to 600 mM, followed by centrifugation at 200,000 × g for 3 h. The pellet was resuspended in G-buffer and dialyzed against G-buffer extensively before a final clarification at 400,000 × g for 40 min. 2 mM MgCl₂ and 10 mM KCl were added to the supernatant to polymerize the G-actin. Actin concentration was determined by measuring the absorbance at 290 nm using an extinction coefficient of 26,600 cm⁻¹M⁻¹.

Skeletal myosin from chicken breasts (Shadow Cross Farm, Colchester VT) and cardiac myosin from rabbit hearts (41321, Pel-Freez Biologicals) were purified by extraction of ground tissue in 150 mM NaPO₄ pH 6.5, 300 mM NaCl, 5 mM MgCl₂, 2 mM MgATP, 2 mM DTT, 1 mM EGTA, 0.5 mM AEBSF, 0.5 mM TLCK and 5 µg/ml leupeptin⁴¹. Myosin was precipitated by a 20-fold dilution with water, and the precipitate resuspended and dialyzed in 25 mM NaPO₄ pH 7.0, 600 mM NaCl, 2 mM MgCl₂, 1 mM DTT, 1 mM NaN₃. 2 mM MgATP was added to the dialyzed myosin and the solution was clarified by centrifugation at 200,000 × g for 3 h. The supernatant was dialyzed against 0.2 M sodium pyrophosphate pH 7.0, 0.5 mM DTT and clarified at 40,000 × g for 20 min. The clarified supernatant was applied to a DEAE-Sephacel ion-exchange column (17-0500-01, Amersham Biosciences) and eluted with a gradient of 0–0.5 M NaCl in 0.2 M sodium pyrophosphate pH 7.0, 0.5 mM DTT. Pure myosin fractions, identified by SDS-PAGE analysis, were dialyzed against 25 mM NaPO₄ pH 7.0, 600 mM NaCl, 2 mM MgCl₂, 1 mM DTT and 1 mM NaN₃. Glycerol was added to 50% and the myosin stored at −20 °C.

Basal and actin-activated ATPase assays

ATPase activity was determined using a linked assay, which couples the regeneration of hydrolyzed ATP to the oxidation of NADH to NAD⁺⁹. 2 mM MgATP was added to a 300 µl aliquot of myosin (basal) or actomyosin (actin-activated), manually transferred to a cuvette, and the decrease in optical density at 340 nm measured as function of time on a Lambda 25 UV/VIS spectrophotometer (Perkin Elmer) with a 360 s data monitoring window sampled every 5 s. Data were fit with a four-parameter logistic curve (Graph Pad Prism v9.3.1). Conditions: 10 mM imidazole pH 7.5, 5 mM KCl, 1 mM MgCl₂, 1 mM EGTA, 1 mM DTT, 1 mM NaN₃, 2 mM MgATP, 5 nM PfMyoA, 55 nM skeletal myosin II, 100 nM cardiac myosin, 50 µM skeletal actin, 1% DMSO, 30 °C. Under these conditions, the actin-activated values for PfMyoA in the absence of inhibitor were 84.2 ± 1.4 s⁻¹ (n = 3) and 9.6 ± 3.4 s⁻¹ in the presence of 100 µM KNX-002.

Motility and actin binding assays

Prior to in vitro motility, PfMyoA was spun at 350,000 × g spin for 20 min in the presence of 1.5 mM MgATP and a three-fold molar excess of skeletal actin. Solutions were added to a nitrocellulose-coated flow cell in 15 µl volumes in the following order. 0.5 mg/ml biotinylated bovine serum albumin (BSA) in buffer A (25 mM imidazole pH 7.5, 150 mM KCl, 4 mM MgCl₂, 1 mM EGTA, 10 mM DTT) was incubated for 1 min. 0.7 mg/ml BSA in buffer A was then incubated for 2 min. Neutravidin (25 µg/ml, Thermo Fisher Scientific) in buffer A was added for 1 min and rinsed out with three additions of buffer A. PfMyoA (120 µg/ml) was added in buffer A with either 1% DMSO or 100 µM KNX-002 and incubated 1 min before 3 washes with buffer A (with 1% DMSO or 100 µM KNX-002). Rhodamine-phalloidin labeled skeletal muscle actin was applied for 30 s followed by one rinse with buffer A (with 1% DMSO or 100 µM KNX-002) and one rinse with buffer B (buffer A plus 0.15% (w/v) methylcellulose, 25 µg/ml PfELC, 25 µg/ml PfMTIP, 50 µg/ml catalase (Sigma), 125 µg/ml glucose oxidase (Sigma), 3 mg/ml glucose). Buffer B containing 2 mM MgATP was added twice to initiate motility. From myosin addition onward, either 1% DMSO or 100 µM KNX-002 in 1% DMSO was present in all solutions. Actin filaments were visualized using an inverted microscope Zeiss Axiovert 10), a Rolera MGi Plus digital camera and the Nikon NIS Elements software package. Filament speeds were tracked and analyzed with the Fast Automated Spud Trekker analysis program (FAST, Spudich laboratory, Stanford University). This online software is free and available for download at http://spudlab.stanford.edu/fast-for-automatic-motility-measurements. Speeds were fit to a Gaussian curve.

Actin binding to myosin was measured with a modified in vitro motility assay. For visualization in apo, ADP or ATP buffers, motility buffer B that contained either no nucleotide, 2 mM MgADP or 2 mM MgATP without methylcellulose was added after the rhodamine-phalloidin actin binding step. The number of actin filaments bound was quantified manually. Conditions: 25 mM imidazole pH 7.5, 150 mM KCl, 4 mM MgCl₂, 1 mM EGTA, 10 mM DTT, 0% methylcellulose, 1% DMSO, 30 °C. 2 mM MgATP or MgADP were added for +ATP or +ADP condition, respectively.

Phosphate burst

Chemical hydrolysis of ATP by myosin was performed by manual mixing under single turnover conditions. PfMyoA (25 µM) was pre incubated with 1% DMSO or KNX-002 (100 µM in 1% DMSO), manually mixed with 20 µM MgATP, aged for 5 s, and then quenched by addition of 0.3 M perchloric acid before quantifying free phosphate as follows⁴². To a 50 µl sample, 200 µl Detection Solution (5.72% (w/v) ammonium molybdate in 6 N HCl, 2.32% (w/v) polyvinyl alcohol and 0.0812% (w/v) malachite green) was added and allowed to incubate for 1 min before adding 50 µl 34% sodium citrate. A phosphate standard curve (0-2 nmoles) was used to convert the optical density signal change at 595 nm to nmoles phosphate. Controls using myosin, dialysis buffer or ATP alone showed undetectable phosphate. Conditions: 10 mM imidazole pH 7.5, 150 mM KCl, 4 mM MgCl₂, 1 mM EGTA, 10 mM DTT, 25 µM PfMyoA, 20 µM MgATP, 1% DMSO, 30 °C.

Actin polymerization assay

Monomeric PfAct1 was polymerized in a buffer containing 10 mM imidazole, pH 7.5, 50 mM KCl, 2 mM MgCl₂, 1 mM EGTA, 0.25% methylcellulose, 2.5 mM MgATP, 10 mM DTT, 0.13 mg/mL glucose oxidase, 50 μg/mL catalase, 3 mg/mL glucose and either 1% DMSO or 100 µm KNX-002 at 37 °C. Filament growth was visualized using 0.5 µM actin–chromobody Emerald (ChromoTek) and quantified as a function of time⁴³. TIRF microscopy recorded with a Nikon ECLIPSE Ti microscope and an Andor EMCCD camera (Andor Technology) run by the Nikon NIS Elements software package. Samples were excited with a 488-nm TIRF-field laser line and emission was observed with a 525/50 filter.

Transient kinetics

All stopped-flow experiments were performed on a KinTek stopped-flow apparatus (KinTek Corporation, model SF-2001). All concentrations stated are after mixing into the stopped-flow cell, except where stated. Light scattering at 295 nm with a 295 nm interference filter orthogonal to the incident light was used to monitor the dissociation of actomyosin (0.2 µM actin and 0.15 µM PfMyoA). Mant-ATP and mant-ADP binding to myosin was measured by exciting at 290 nm and monitoring emission light that passed through a 400 nm long pass filter, so that only nucleotide bound at the active site is monitored via energy transfer from a Trp. For mant-nucleotide binding experiments in the presence of inhibitor, 100 µM KNX-002 and 1% DMSO were present in both syringes. All traces were analyzed using the software package provided by KinTek and fit to either single or double exponentials. Multiple time courses (usually 3-8) were averaged prior to curve fitting. Conditions: 10 mM HEPES pH 7.5, 50 mM KCl, 4 mM MgCl₂, 1 mM EGTA, 1 mM DTT, 1% DMSO, 30 °C.

Crystallization, data processing, structure determination and refinement

Full-length PfMyoA with bound light chains PfELC and MTIP-ΔN (lacking residues 1-E60) was co-crystallized with or without KNX-002. PfMyoA/ELC/ MTIP-ΔN at 10.6 mg/ml was incubated with 2 mM Mg.ADP-gamma-S (ATPγS) for 20 min (Apo-PfMyoA). PfMyoA-KNX-002 crystals were obtained with and without the incubation of 2 mM Mg.ADP-gamma-S (ATPγS) for 20 min and 0.5 mM KNX-002 for 40 min. All the samples were centrifugated at 11,000 × g for 15 min at 4 °C before crystallizing assays. Both crystals of PfMyoA/ELC/MTIP-ΔN were obtained at 4 °C by the hanging drop vapor diffusion method from a 1:1 (v:v) of protein and mother liquor. The crystallization buffer is 2.0 M ammonium sulfate, 0.1 M sodium HEPES pH 7,5, 4% PEG400. The crystals were transferred in the cryoprotection containing the mother liquor +25% glycerol (v:v) and immediately flash frozen in liquid nitrogen.

X-ray datasets were collected at the ESRF Synchrotron, on the ID30B beamline⁴⁴), at 100 K with the following parameters: PfMyoA/ATPγS/Apo (λ = 0.9677 Å, 46.8% transmission, flux start 7.54e¹¹ ph/sec); PfMyoA/ATPγS/KNX-002 (λ = 0.9687 Å, 1.2% transmission, flux start 9.89e¹² ph/sec); PfMyoA/NF/KNX-002 (λ = 1.07216 Å, 30.6% transmission, flux start 6.83e¹¹ ph/sec). Diffraction datasets were processed using XDS⁴⁵ and AutoPROC⁴⁶. Both crystal forms (PfMyoA/ATPγS/Apo), (PfMyoA/ATPγS/KNX-002) and (PfMyoA/NF/KNX-002) belong to the space group P2₁2₁2₁. The molecular replacement solution was obtained by using Phaser⁴⁷ using the PDB coordinates from 6YCY¹⁰ without solvent and water as model target. The 3D structure of compound KNX-002 and the related restraints were generated using Elbow⁴⁸. The models were manually refined using Coot⁴⁹. The refinement was performed using Buster⁵⁰ and Phenix⁵¹. The final Ramachandran for favored, allowed and outliers are 97.25%, 2.65%, 0.09% for (PfMyoA/ATPγS/Apo); 96.51%; 3.49%, 0% for (PfMyoA/ATPγS/KNX-002) and 97.15%; 2.85%, 0% for (PfMyoA/NF/KNX-002), respectively. The atomic coordinates and structure factors have been deposited in the Protein Data Bank⁵², www.pdb.org, with accession numbers 8A12 (PfMyoA/ATPγS/Apo), 8CDQ (PfMyoA/ATPγS/KNX-002) and 8CDM (PfMyoA/NF/KNX-002).

Analysis of the drug binding pockets

The residues involved in drug binding were automatically determined with the software LigPlot+⁵³. Default set up interaction cut off at 3.9 Å, but we investigated manually longer range interactions (yet <5 Å) by visualization with the PyMOL software⁵⁴. The figure panels were created and manually edited with LigPlot+.

Effects of KNX-002 on parasite asexual blood-stage growth

Asexual parasite blood stage growth (measuring the ability of parasites to invade, replicate, exit and reinvade erythrocytes) was undertaken using the SYBR Green asexual growth assay, undertaken largely as published⁵⁵. In brief 96-well black clear bottom plates (Corning) were pre-printed with test compound and normalized with DMSO (Merck) to 0.5% of a total assay volume of 100 μl. Highly synchronized ring stage parasites and blood was added to each well so that the final parasitaemia was 2% and the hematocrit was 1%. The compound was incubated with parasites for 72 h before being frozen at −20 °C (to aid with cell lysis). The plate was thawed on ice and a lysis buffer (20 mM Tris pH7.5 (Merck), 5 mM EDTA (Merck), 0.008% w/vol saponin (Merck), 0.08% vol/vol triton-x100 (Merck) and SYBR-Green I (Thermo Fisher Scientific) at a final concentration of 0.02% vol/vol). The 96-well plate was incubated for 1 h at RTP before each well was assayed for fluorescence using GFP filters (Excitation 485 nm/Emission 535 nm) on a microplate reader (TECAN).

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

The atomic models and crystallographic data of PfMyoA/ATPγS/Apo, PfMyoA/ATPγS/KNX-002 and PfMyoA/NF/KNX-002 have been deposited on the PDB under the accession codes 8A12, 8CDQ and 8CDM, respectively. Reference structures used in this work are 1YV3, 6I7D and 6YCY. Source data are provided as a Source Data file. Source data are provided with this paper.

References

Talman, A. M., Domarle, O., McKenzie, F. E., Ariey, F. & Robert, V. Gametocytogenesis: the puberty of Plasmodium falciparum. Malar. J. 3, 24 (2004).
Article PubMed PubMed Central Google Scholar
Phillips, M. A. et al. Malaria. Nat. Rev. Dis. Prim. 3, 17050 (2017).
Article PubMed Google Scholar
Organization, W. H. World malaria report 2021 (World Health Organization, 2021).
Haldar, K., Bhattacharjee, S. & Safeukui, I. Drug resistance in Plasmodium. Nat. Rev. Microbiol. 16, 156–170 (2018).
Article CAS PubMed PubMed Central Google Scholar
Balikagala, B. et al. Evidence of artemisinin-resistant malaria in Africa. N. Engl. J. Med. 385, 1163–1171 (2021).
Article CAS PubMed Google Scholar
Laurens, M. B. RTS,S/AS01 vaccine (Mosquirix^TM): an overview. Hum. Vaccin. Immunother. 16, 480–489 (2020).
Article CAS PubMed Google Scholar
Tardieux, I. & Baum, J. Reassessing the mechanics of parasite motility and host-cell invasion. J. Cell Biol. 214, 507–515 (2016).
Article CAS PubMed PubMed Central Google Scholar
Frenal, K., Dubremetz, J.-F., Lebrun, M. & Soldati-Favre, D. Gliding motility powers invasion and egress in Apicomplexa. Nat. Rev. Microbiol. 15, 645–660 (2017).
Article CAS PubMed Google Scholar
Robert-Paganin, J. et al. Plasmodium myosin A drives parasite invasion by an atypical force generating mechanism. Nat. Commun. 10, 3286 (2019).
Article ADS PubMed PubMed Central Google Scholar
Moussaoui, D. et al. Full-length Plasmodium falciparum myosin A and essential light chain PfELC structures provide new anti-malarial targets. Elife 9, e60581 (2020).
Article CAS PubMed PubMed Central Google Scholar
Siden-Kiamos, I. et al. Stage-specific depletion of myosin A supports an essential role in motility of malarial ookinetes. Cell. Microbiol. 13, 1996–2006 (2011).
Article CAS PubMed Google Scholar
Wall, R. J. et al. Systematic analysis of Plasmodium myosins reveals differential expression, localisation, and function in invasive and proliferative parasite stages. Cell. Microbiol. 21, e13082 (2019).
Article PubMed PubMed Central Google Scholar
Malik, F. I. et al. Cardiac myosin activation: A potential therapeutic approach for systolic heart failure. Science 331, 1439–1443 (2011).
Article ADS CAS PubMed PubMed Central Google Scholar
Planelles-Herrero, V. J., Hartman, J. J., Robert-Paganin, J., Malik, F. I. & Houdusse, A. Mechanistic and structural basis for activation of cardiac myosin force production by omecamtiv mecarbil. Nat. Commun. 8, 190 (2017).
Article ADS PubMed PubMed Central Google Scholar
Green, E. M. et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351, 617–621 (2016).
Article ADS CAS PubMed PubMed Central Google Scholar
Sirigu, S. et al. Highly selective inhibition of myosin motors provides the basis of potential therapeutic application. Proc. Natl Acad. Sci. USA 113, E7448–E7455 (2016).
Article CAS PubMed PubMed Central Google Scholar
Rauscher, A. Á., Gyimesi, M., Kovács, M. & Málnási-Csizmadia, A. Targeting Myosin by Blebbistatin derivatives: optimization and pharmacological potential. Trends Biochem. Sci. 43, 700–713 (2018).
Article CAS PubMed Google Scholar
Manstein, D. J. & Preller, M. Small molecule effectors of myosin function. Adv. Exp. Med. Biol. 1239, 61–84 (2020).
Article CAS PubMed Google Scholar
Day, S. M., Tardiff, J. C. & Ostap, E. M. Myosin modulators: emerging approaches for the treatment of cardiomyopathies and heart failure. J. Clin. Invest. 132, e148557 (2022).
Article CAS PubMed PubMed Central Google Scholar
Gyimesi, M. et al. Single residue variation in skeletal muscle myosin enables direct and selective drug targeting for spasticity and muscle stiffness. Cell 183, 335–346.e13 (2020).
Article CAS PubMed PubMed Central Google Scholar
Utter, M. S., Ryba, D. M., Li, B. H., Wolska, B. M. & Solaro, R. J. Omecamtiv mecarbil, a cardiac myosin activator, increases Ca2+ sensitivity in myofilaments with a dilated cardiomyopathy mutant tropomyosin E54K. J. Cardiovasc. Pharmacol. 66, 347–353 (2015).
Article CAS PubMed PubMed Central Google Scholar
Amgen, cytokinetics and servier announce start of METEORIC-HF, the second phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure. https://wwwext.amgen.com/media/news-releases/2019/02/amgen-cytokinetics-and-servier-announce-start-of-meteorichf-the-second-phase-3-clinical-trial-of-omecamtiv-mecarbil-in-patients-with-heart-failure/.
Kelsen, A. et al. The class XIV myosin of Toxoplasma gondii, TgMyoA, is druggable in an animal model of infection. bioRxiv https://doi.org/10.1101/2022.09.09.507210 (2023).
Blake, T. C. A., Haase, S. & Baum, J. Actomyosin forces and the energetics of red blood cell invasion by the malaria parasite Plasmodium falciparum. PLOS Pathog. 16, e1009007 (2020).
Article CAS PubMed PubMed Central Google Scholar
Yount, R. G., Lawson, D. & Rayment, I. Is myosin a ‘back door’ enzyme? Biophys. J. 68, 44S–47S (1995).
CAS PubMed PubMed Central Google Scholar
Robert-Paganin, J., Pylypenko, O., Kikuti, C., Sweeney, H. L. & Houdusse, A. Force generation by myosin motors: a structural perspective. Chem. Rev. 120, 5–35 (2020).
Article CAS PubMed Google Scholar
Sweeney, H. L., Houdusse, A. & Robert-Paganin, J. Myosin structures. Adv. Exp. Med. Biol. 1239, 7–19 (2020).
Article CAS PubMed Google Scholar
Allingham, J. S., Smith, R. & Rayment, I. The structural basis of blebbistatin inhibition and specificity for myosin II. Nat. Struct. Mol. Biol. 12, 378–379 (2005).
Article CAS PubMed Google Scholar
Kiani, F. A. & Fischer, S. Advances in quantum simulations of ATPase catalysis in the myosin motor. Curr. Opin. Struct. Biol. 31, 115–123 (2015).
Article CAS PubMed Google Scholar
Chakraborti, A., Baldo, A. P., Tardiff, J. C. & Schwartz, S. D. Investigation of the recovery stroke and ATP hydrolysis and changes caused due to the cardiomyopathic point mutations in human cardiac β myosin. J. Phys. Chem. B 125, 6513–6521 (2021).
Article CAS PubMed PubMed Central Google Scholar
Robert-Paganin, J. et al. The actomyosin interface contains an evolutionary conserved core and an ancillary interface involved in specificity. Nat. Commun. 12, 1892 (2021).
Article ADS CAS PubMed PubMed Central Google Scholar
Kovács, M., Tóth, J., Hetényi, C., Málnási-Csizmadia, A. & Sellers, J. R. Mechanism of blebbistatin inhibition of myosin II. J. Biol. Chem. 279, 35557–35563 (2004).
Article PubMed Google Scholar
Bauer, C. B., Holden, H. M., Thoden, J. B., Smith, R. & Rayment, I. X-ray structures of the Apo and MgATP-bound States of Dictyostelium discoideum myosin motor domain*. J. Biol. Chem. 275, 38494–38499 (2000).
Article CAS PubMed Google Scholar
Trivedi, D. V. et al. A small-molecule myosin inhibitor as a targeted multi-stage antimalarial. bioRxiv https://doi.org/10.1101/2022.09.09.507317 (2022).
Yahiya, S., Rueda-Zubiaurre, A., Delves, M. J., Fuchter, M. J. & Baum, J. The antimalarial screening landscape-looking beyond the asexual blood stage. Curr. Opin. Chem. Biol. 50, 1–9 (2019).
Article CAS PubMed PubMed Central Google Scholar
Burrows, J. N. et al. New developments in anti-malarial target candidate and product profiles. Malar. J. 16, 26 (2017).
Article PubMed PubMed Central Google Scholar
Bookwalter, C. S. et al. Reconstitution of the core of the malaria parasite glideosome with recombinant Plasmodium class XIV myosin A and Plasmodium actin. J. Biol. Chem. 292, 19290–19303 (2017).
Article CAS PubMed PubMed Central Google Scholar
Cronan, J. E. J. Biotination of proteins in vivo. A post-translational modification to label, purify, and study proteins. J. Biol. Chem. 265, 10327–10333 (1990).
Article CAS PubMed Google Scholar
Li, S. J. & Cronan, J. E. J. Growth rate regulation of Escherichia coli acetyl coenzyme A carboxylase, which catalyzes the first committed step of lipid biosynthesis. J. Bacteriol. 175, 332–340 (1993).
Article CAS PubMed PubMed Central Google Scholar
Pardee, J. D. & Spudich, J. A. Purification of muscle actin. Methods Enzymol. https://doi.org/10.1016/0076-6879(82)85020-9 (1982).
Margossian, S. S. & Lowey, S. Preparation of myosin and its subfragments from rabbit skeletal muscle. Methods Enzymol. 85 Pt B, 55–71 (1982).
Article CAS PubMed Google Scholar
Henkel, R. D., VandeBerg, J. L. & Walsh, R. A. A microassay for ATPase. Anal. Biochem. 169, 312–318 (1988).
Article CAS PubMed Google Scholar
Lu, H., Fagnant, P. M. & Trybus, K. M. Unusual dynamics of the divergent malaria parasite PfAct1 actin filament. Proc. Natl Acad. Sci. USA 116, 20418–20427 (2019).
Article ADS CAS PubMed PubMed Central Google Scholar
McCarthy, A. A. et al. ID30B {-} a versatile beamline for macromolecular crystallography experiments at the ESRF. J. Synchrotron Radiat. 25, 1249–1260 (2018).
Article CAS PubMed PubMed Central Google Scholar
Kabsch, W. XDS. Acta Crystallogr. Sect. D. Biol. Crystallogr. 66, 125–132 (2010).
Article CAS Google Scholar
Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D. Biol. Crystallogr. 67, 293–302 (2011).
Article CAS PubMed PubMed Central Google Scholar
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
Article CAS PubMed PubMed Central Google Scholar
Moriarty, N. W., Grosse-Kunstleve, R. W. & Adams, P. D. electronic Ligand Builder and Optimization Workbench (eLBOW): a tool for ligand coordinate and restraint generation. Acta Crystallogr. D. Biol. Crystallogr. 65, 1074–1080 (2009).
Article CAS PubMed PubMed Central Google Scholar
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D. Biol. Crystallogr. 60, 2126–2132 (2004).
Article Google Scholar
Bricogne, G. et al. BUSTER version 2.10.2 (United Kingdom Globle Phasing Ltd., 2017).
Liebschner, D. et al. Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr. Sect. D. Struct. Biol. 75, 861–877 (2019).
Article CAS Google Scholar
Berman, H. M. et al. The protein data bank. Nucleic Acids Res. 28, 235–242 (2000).
Article ADS CAS PubMed PubMed Central Google Scholar
Laskowski, R. A. & Swindells, M. B. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 51, 2778–2786 (2011).
Article CAS PubMed Google Scholar
Schrodinger LLC & DeLano, W. L. The PyMOL molecular graphics system, Version 2.0 (2020). Retrieved from http://www.pymol.org/pymol.
Matthews, H., Deakin, J., Rajab, M., Idris-Usman, M. & Nirmalan, N. J. Investigating antimalarial drug interactions of emetine dihydrochloride hydrate using CalcuSyn-based interactivity calculations. PLoS One 12, e0173303 (2017).
Article PubMed PubMed Central Google Scholar
Gyimesi, M. et al. Improved Inhibitory and Absorption, Distribution, Metabolism, Excretion, and Toxicology (ADMET) properties of blebbistatin derivatives indicate that blebbistatin scaffold is ideal for drug development targeting myosin-2. J. Pharmacol. Exp. Ther. 376, 358–373 (2021).
Article PubMed Google Scholar

Download references

Acknowledgements

This work was supported by NIH grant R01AI 132378 to K.M.T. and A.H., a grant from the Human Frontier Science Program (RGY006/2016) to J.B. and A.H., grants from the Wellcome (Investigator Award to J.B., 100993/Z/13/Z) and the Medicines for Malaria Venture (RD-08-2800) to J.B. We thank Cytokinetics for providing purified actin for the screen and access to their high-throughput screening library, infrastructure and staff. We are grateful to Dr. James Spudich (CEO of Kainomyx) for giving us the opportunity to study KNX-002 in the Plasmodium system via a Continuing Research Agreement between Kainomyx and the University of Vermont (K.M.T.), and Kainomyx and the Institut Curie (A.H.). We acknowledge the ESRF for providing in-house research beamtime on the ID30B, especially Dr. Andrew McCarthy. We thank Dr. James Spudich and Dr. Kathleen Ruppel for critical reading of the manuscript, and Dr. James Spudich for useful suggestions regarding the motility experiments. We thank Dr. Gordon Leonard (ESRF, Grenoble, France) for critical reading of the manuscript, and Dr. Hailong Lu (University of Vermont) for performing the TIRF polymerization assay on PfAct1.

Author information

Dihia Moussaoui
Present address: Structural Biology group, European Synchrotron Radiation Facility (ESRF), 71, Avenue des Martyrs, 38000, Grenoble, France
These authors contributed equally: Dihia Moussaoui, James P. Robblee, Julien Robert-Paganin.

Authors and Affiliations

Structural Motility, Institut Curie, Université Paris Sciences et Lettres, Sorbonne Université, CNRS UMR144, 75248, Paris, France
Dihia Moussaoui, Julien Robert-Paganin, Daniel Auguin & Anne Houdusse
Department of Molecular Physiology & Biophysics, University of Vermont, Burlington, VT, USA
James P. Robblee, Patricia M. Fagnant, Jill E. Macfarlane & Kathleen M. Trybus
Laboratoire de Biologie des Ligneux et des Grandes Cultures (LBLGC), Université d’Orléans, INRAE, USC1328, Orléans, France
Daniel Auguin
Department of Life Sciences, Imperial College London, Exhibition Road, South Kensington, London, SW7 2AZ, UK
Fabio Fisher & Jake Baum
Center for Emerging and Neglected Diseases, Drug Discovery Center, Berkeley, CA, USA
Julia Schaletzky & Eddie Wehri
Structural Biology group, European Synchrotron Radiation Facility (ESRF), 71, Avenue des Martyrs, 38000, Grenoble, France
Christoph Mueller-Dieckmann
School of Medical Sciences, Faculty of Medicine & Health, UNSW Sydney, Kensington, NSW, 2052, Australia
Jake Baum

Authors

Dihia Moussaoui
View author publications
You can also search for this author in PubMed Google Scholar
James P. Robblee
View author publications
You can also search for this author in PubMed Google Scholar
Julien Robert-Paganin
View author publications
You can also search for this author in PubMed Google Scholar
Daniel Auguin
View author publications
You can also search for this author in PubMed Google Scholar
Fabio Fisher
View author publications
You can also search for this author in PubMed Google Scholar
Patricia M. Fagnant
View author publications
You can also search for this author in PubMed Google Scholar
Jill E. Macfarlane
View author publications
You can also search for this author in PubMed Google Scholar
Julia Schaletzky
View author publications
You can also search for this author in PubMed Google Scholar
Eddie Wehri
View author publications
You can also search for this author in PubMed Google Scholar
Christoph Mueller-Dieckmann
View author publications
You can also search for this author in PubMed Google Scholar
Jake Baum
View author publications
You can also search for this author in PubMed Google Scholar
Kathleen M. Trybus
View author publications
You can also search for this author in PubMed Google Scholar
Anne Houdusse
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

A.H. and K.M.T. designed and directed the research. D.M. crystallized PfMyoA and PfMyoA complexed to KNX-002. D.M. and C.M.D. collected the data. D.M. and J.R.P. processed the data, solved and refined the structures. J.P.R. performed the in vitro functional assays. P.M.F. and J.E.M. expressed and purified PfMyoA. F.F. performed the parasitemia assays. J.S. and E.W. developed the screening assay and performed the high-throughput screen and hit characterization for CK2140597/KNX-002 while at Cytokinetics. D.M., J.P.R., D.A., J.R.P., K.M.T. and A.H. analyzed and discussed the results. D.M., J.R.P. and A.H. wrote the initial version of the paper, with the help of J.P.R., D.A., J.B. and K.M.T. All the authors were involved in reviewing and editing the paper. J.B., J.R.P., K.M.T. and A.H. were involved in project administration. J.B., K.M.T. and A.H. provided funding.

Corresponding authors

Correspondence to Kathleen M. Trybus or Anne Houdusse.

Ethics declarations

Competing interests

A.H. receives research funding from Cytokinetics and consults for Kainomyx. All other authors have no competing interests.

Peer review

Peer review information

Nature Communications thanks Michael Ostap and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Peer Review File

Description of Additional Supplementary Files

Supplementary Movie 1

Supplementary Movie 2

Supplementary Movie 3

Reporting Summary

Source data

Source Data

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Moussaoui, D., Robblee, J.P., Robert-Paganin, J. et al. Mechanism of small molecule inhibition of Plasmodium falciparum myosin A informs antimalarial drug design. Nat Commun 14, 3463 (2023). https://doi.org/10.1038/s41467-023-38976-7

Download citation

Received: 31 July 2022
Accepted: 24 May 2023
Published: 12 June 2023
DOI: https://doi.org/10.1038/s41467-023-38976-7

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.